Literature DB >> 8649782

The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction.

A Kilbey1, E J Black, M Unlu, D A Gillespie.   

Abstract

We have investigated the expression of Jun family proteins and composition of AP-1 in chicken embryo fibroblasts before and after transformation by the v-Jun oncoprotein of ASV17. We show that p39 c-Jun is the predominant Jun family protein expressed in normal fibroblasts, and that heterodimers of c-Jun and Fos-related partners (Fra's) account for the majority of the AP-1 DNA binding activity. Unexpectedly, because ASV17-transformed fibroblasts do not express p39 c-Jun, v-Jun replaces c-Jun as the predominant AP-1 constituent in association with similar or identical Fra's. This substitution has little effect on the overall level of TRE-specific DNA binding activity, however it results in a profound reduction in TRE-dependent transcriptional activity and a striking defect in signal-regulated phosphorylation of the Jun component of AP-1; whilst agonists of SAPK/JNK kinases trigger transient N-terminal phosphorylation of c-Jun in normal fibroblasts, no corresponding modification of v-Jun occurs in ASV17-transformed cells. Because SAPK/JNK-mediated phosphorylation is thought to regulate c-Jun transcriptional activity and thereby cellular gene expression in response to extracellular signals, we propose that subversion of this signal transduction process by v-Jun is likely to contribute to oncogenesis by ASV17.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649782

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation.

Authors:  S l Fu; I Bottoli; M Goller; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

2.  Hormone-regulatable neoplastic transformation induced by a Jun-estrogen receptor chimera.

Authors:  U Kruse; J S Iacovoni; M E Goller; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

3.  Autocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation.

Authors:  H van Dam; S Huguier; K Kooistra; J Baguet; E Vial; A J van der Eb; P Herrlich; P Angel; M Castellazzi
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

4.  Runx regulation of sphingolipid metabolism and survival signaling.

Authors:  Anna Kilbey; Anne Terry; Alma Jenkins; Gillian Borland; Qifeng Zhang; Michael J O Wakelam; Ewan R Cameron; James C Neil
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

5.  v-Jun overrides the mitogen dependence of S-phase entry by deregulating retinoblastoma protein phosphorylation and E2F-pocket protein interactions as a consequence of enhanced cyclin E-cdk2 catalytic activity.

Authors:  W Clark; E J Black; A MacLaren; U Kruse; N LaThangue; P K Vogt; D A Gillespie
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

6.  Transforming growth factor beta (TGFbeta) mediates Schwann cell death in vitro and in vivo: examination of c-Jun activation, interactions with survival signals, and the relationship of TGFbeta-mediated death to Schwann cell differentiation.

Authors:  D B Parkinson; Z Dong; H Bunting; J Whitfield; C Meier; H Marie; R Mirsky; K R Jessen
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

7.  Insulin-stimulated expression of c-fos, fra1 and c-jun accompanies the activation of the activator protein-1 (AP-1) transcriptional complex.

Authors:  M R Griffiths; E J Black; A A Culbert; M Dickens; P E Shaw; D A Gillespie; J M Tavaré
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

8.  Chk1 regulates the density of active replication origins during the vertebrate S phase.

Authors:  Apolinar Maya-Mendoza; Eva Petermann; David A F Gillespie; Keith W Caldecott; Dean A Jackson
Journal:  EMBO J       Date:  2007-05-10       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.